Collectively, the evidence supports a prognostic role of p16INK4a expression in lung cancer and the variability between different studies can be attributed to different methodological approaches, especially p16INK4a scoring, different sample sizes, and different histological subtypes. The gene discussed is CDKN2A; the disease is lung cancer.